We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Roche has partnered with Recursion to generate up to 40 new neuroscience and cancer therapies using the Utah-based biotech firm’s machine-learning drug discovery platform. Read More
Allergan has agreed to pay $200 million to resolve New York-based claims that it helped facilitate the state’s opioid crisis through deceptive marketing. Read More
The Pfizer/BioNTech and Moderna COVID-19 vaccines are 25-40 times less effective against the new Omicron variant than the original strain and Delta variants, two new laboratory studies have found. Read More
The FDA has granted AstraZeneca’s long-acting antibody combination Evusheld an Emergency Use Authorization (EUA) for preventing COVID-19 in adults and children 12 years of age and older with weak immune systems. Read More
An FDA advisory committee unanimously rejected recommending approval of Reata Pharmaceuticals’ bardoxolone methyl as a treatment for patients 12 years and up with chronic kidney disease caused by Alport syndrome (AS), a rare genetic disorder. Read More
In the U.S., an FDA advisory committee narrowly backed authorizing molnupiravir last week, but the agency has yet to approve the COVID-19 pill for emergency use. Read More
The WHO said the evidence was less certain for severe and critically ill COVID-19 patients and suggested trials continue for this subgroup to gather more data. Read More
The FDA offered guidance for sponsors of individualized drugs developed for use against life-threatening genetic diseases in two draft guidances released yesterday. Read More